Symbols

OTLK

Outlook Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 3

Consensus Rating "Strong Buy"

MACD Death Cross

High Gross Profit Margin

Significant Net Income Decline

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About OTLK

Outlook Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for various ophthalmic indications

Industry

Pharmaceutical

Established Date

01/05/2010

Listing Date

06/14/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

09-30

Website

www.outlooktherapeutics.com

Security Type

Common stock

Office address

111 S. Wood Avenue Unit #100 Iselin New Jersey 08852

Business

Introduction

Outlook Therapeutics, Inc., was incorporated in New Jersey on January 5, 2010. The company is a biopharmaceutical company that is the first to obtain marketing authorization for ONS-5010/LYTENAVA (bevacizumab-gamma) ophthalmic preparations in the EU or EU, UK or UK for the treatment of wet age-related macular degeneration, or wet AMD.

Company Financials

EPS

OTLK has released its 2025 Q3 earnings. EPS was reported at -0.55, versus the expected -0.39, missing expectations. The chart below visualizes how OTLK has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

OTLK has released its 2025 Q4 earnings report, with revenue of -91.79K, reflecting a YoY change of NaN%, and net profit of -13.29M, showing a YoY change of -333.56%. The Sankey diagram below clearly presents OTLK's revenue sources and cost distribution.